A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of Cvx-096 In Type 2 Diabetic Adult Subjects

Trial Profile

A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of Cvx-096 In Type 2 Diabetic Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs PF 4856883 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Jul 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2011 Planned end date changed from 1 Jul 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top